Cargando…

Treatment of Symptomatic Polyneuropathy With Actovegin in Type 2 Diabetic Patients

OBJECTIVE: To evaluate the efficacy and safety of actovegin in patients with diabetic polyneuropathy. RESEARCH DESIGN AND METHODS: In this multicenter, randomized, double-blind trial, 567 patients with type 2 diabetes received 20 intravenous infusions of actovegin (2,000 mg/day) (n = 281) or placebo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ziegler, Dan, Movsesyan, Lusine, Mankovsky, Boris, Gurieva, Irina, Abylaiuly, Zhangentkhan, Strokov, Igor
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2009
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713653/ https://www.ncbi.nlm.nih.gov/pubmed/19470838 http://dx.doi.org/10.2337/dc09-0545

Ejemplares similares

Neuroprotective and Anti-Oxidative Effects of the Hemodialysate Actovegin on Primary Rat Neurons in Vitro
por: Elmlinger, Martin W., et al.
Publicado: (2011)

Actovegin® reduces PMA-induced inflammation on human cells
por: Reichl, Franz-Xaver, et al.
Publicado: (2020)

Correction to: Actovegin® reduces PMA‑induced inflammation on human cells
por: Reichl, Franz-Xaver, et al.
Publicado: (2021)

A Splice Variant of GNB3 and Peripheral Polyneuropathy in Type 1 Diabetes
por: Chistiakov, Dimitry A., et al.
Publicado: (2009)

Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats
por: Kurkin, Denis V., et al.
Publicado: (2021)

Treatment with Actovegin improves spatial learning and memory in rats following transient forebrain ischaemia
por: Meilin, Sigal, et al.
Publicado: (2014)

Actovegin in the management of patients after ischemic stroke: A systematic review
por: la Fleur, Philip, et al.
Publicado: (2022)

ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment
por: Guekht, Alla, et al.
Publicado: (2017)

Treatment with α-Lipoic Acid over 16 Weeks in Type 2 Diabetic Patients with Symptomatic Polyneuropathy Who Responded to Initial 4-Week High-Dose Loading
por: Garcia-Alcala, Hector, et al.
Publicado: (2015)

Current concepts in the management of diabetic polyneuropathy
por: Ziegler, Dan, et al.
Publicado: (2020)

Efficacy and Safety of Lacosamide in Painful Diabetic Neuropathy
por: Ziegler, Dan, et al.
Publicado: (2010)

Current Synthesis and Systematic Review of Main Effects of Calf Blood Deproteinized Medicine (Actovegin(®)) in Ischemic Stroke
por: Firan, Florentina Carmen, et al.
Publicado: (2020)

Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy
por: McIlduff, Courtney E, et al.
Publicado: (2011)

Recent updates in the treatment of diabetic polyneuropathy
por: Fan, Qihua, et al.
Publicado: (2022)

A Randomised, Double-Blind, Placebo-Controlled Trial of Actovegin in Patients with Post-Stroke Cognitive Impairment: ARTEMIDA Study Design
por: Guekht, Alla, et al.
Publicado: (2013)

Lower serum extracellular superoxide dismutase levels are associated with polyneuropathy in recent-onset diabetes
por: Strom, Alexander, et al.
Publicado: (2017)

Relationship between the Diabetic Polyneuropathy Index and the Neurological Findings of Diabetic Polyneuropathy
por: Hemmi, Shoji, et al.
Publicado: (2020)

BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy
por: Bönhof, Gidon J, et al.
Publicado: (2022)

Postchallenge Hyperglycemia Is Positively Associated With Diabetic Polyneuropathy: The KORA F4 study
por: Bongaerts, Brenda W.C., et al.
Publicado: (2012)

Deficits in systemic biomarkers of neuroinflammation and growth factors promoting nerve regeneration in patients with type 2 diabetes and polyneuropathy
por: Ziegler, Dan, et al.
Publicado: (2019)

The 8-Week Efficacy of Frequency Rhythmic Electrical Modulated System (FREMS) as an Add-on Therapy in the Treatment of Symptomatic Diabetic Peripheral Polyneuropathy
por: Gorczyca-Siudak, Daria, et al.
Publicado: (2022)

Interaction between magnesium and methylglyoxal in diabetic polyneuropathy and neuronal models
por: Strom, Alexander, et al.
Publicado: (2020)

Update on the management of diabetic polyneuropathies
por: Shakher, Jayadave, et al.
Publicado: (2011)

Sudomotor Testing of Diabetes Polyneuropathy
por: Krieger, Sarah-Maria, et al.
Publicado: (2018)

Heart Rate Variability and Sensorimotor Polyneuropathy in Type 1 Diabetes
por: Orlov, Steven, et al.
Publicado: (2012)

Peripheral Polyneuropathy and Cognitive Impairment in Type II Diabetes Mellitus
por: Elsharkawy, Rasha Elbialy, et al.
Publicado: (2021)

A Review of Alternative Treatment Options in Diabetic Polyneuropathy
por: Zaheer, Arsalan, et al.
Publicado: (2021)

Subclinical Inflammation and Diabetic Polyneuropathy: MONICA/KORA Survey F3 (Augsburg, Germany)
por: Herder, Christian, et al.
Publicado: (2009)

Methylglyoxal products in pre-symptomatic type 1 diabetes
por: Shuck, Sarah C., et al.
Publicado: (2023)

Polyneuropathy is inadequately treated despite increasing symptom intensity in individuals with and without diabetes (PROTECT follow‐up study)
por: Ziegler, Dan, et al.
Publicado: (2020)

Association between Diabetic Polyneuropathy and Cardiovascular Complications in Type 2 Diabetic Patients
por: Chung, Jin Ook, et al.
Publicado: (2011)

Axonal swellings are related to type 2 diabetes, but not to distal diabetic sensorimotor polyneuropathy
por: Karlsson, Pall, et al.
Publicado: (2021)

Diabetic Polyneuropathy in Type 1 and Type 2 Diabetes Mellitus: A Cross-Sectional Study
por: Hindi, Emad, et al.
Publicado: (2022)

Impaired Distal Thermoregulation in Diabetes and Diabetic Polyneuropathy
por: Rutkove, Seward B., et al.
Publicado: (2009)

Efficacy and Safety of Antioxidant Treatment With α-Lipoic Acid Over 4 Years in Diabetic Polyneuropathy: The NATHAN 1 trial
por: Ziegler, Dan, et al.
Publicado: (2011)

Focus on nerve fiber type: A diagnostic strategy for diabetic polyneuropathy
por: Hernandez Fustes, Otto Jesus
Publicado: (2020)

Serine supplementation: Is it a new option for the treatment of diabetic polyneuropathy?
por: Mizukami, Hiroki
Publicado: (2023)

Ranirestat for the Management of Diabetic Sensorimotor Polyneuropathy
por: Bril, Vera, et al.
Publicado: (2009)

Pathways in the Diagnosis and Management of Diabetic Polyneuropathy
por: Kaku, Michelle, et al.
Publicado: (2015)

Conduction Slowing in Diabetic Sensorimotor Polyneuropathy
por: Dunnigan, Samantha K., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_vnamu8ifjj0cubaobvj52brbso